FR24C1053I2 - Utilisation du delgocitinib pour le traitement de l'eczéma des mains chronique - Google Patents

Utilisation du delgocitinib pour le traitement de l'eczéma des mains chronique

Info

Publication number: FR24C1053I2
Authority: FR; France
Prior art keywords: delgocitinib; treatment; hand eczema; chronic hand; chronic
Prior art date: 2016-01-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR24C1053C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Leo Pharma AS

Original Assignee

Leo Pharma AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-21

Filing date

2024-12-15

Publication date

2025-12-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55236207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR24C1053(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2024-12-15 Application filed by Leo Pharma AS filed Critical Leo Pharma AS

2025-02-21 Publication of FR24C1053I1 publication Critical patent/FR24C1053I1/fr

2025-12-05 Application granted granted Critical

2025-12-05 Publication of FR24C1053I2 publication Critical patent/FR24C1053I2/fr

Status Active legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Plant Substances (AREA)
Storage Of Fruits Or Vegetables (AREA)

FR24C1053C 2016-01-21 2024-12-15 Utilisation du delgocitinib pour le traitement de l'eczéma des mains chronique Active FR24C1053I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP16152215		2016-01-21
PCT/EP2017/051133 WO2017125523A1 (fr)	2016-01-21	2017-01-20	Traitement de l'eczéma des mains

Publications (2)

Publication Number	Publication Date
FR24C1053I1 FR24C1053I1 (fr)	2025-02-21
FR24C1053I2 true FR24C1053I2 (fr)	2025-12-05

Family

ID=55236207

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR24C1053C Active FR24C1053I2 (fr)	2016-01-21	2024-12-15	Utilisation du delgocitinib pour le traitement de l'eczéma des mains chronique

Country Status (31)

Country	Link
US (2)	US20200397787A1 (fr)
EP (2)	EP4257205A3 (fr)
JP (1)	JP6929860B2 (fr)
KR (2)	KR20250088666A (fr)
CN (3)	CN108472297A (fr)
AU (3)	AU2017209932A1 (fr)
BR (1)	BR112018014769A2 (fr)
CA (1)	CA3010547A1 (fr)
CY (2)	CY1126388T1 (fr)
DK (1)	DK3405197T3 (fr)
ES (1)	ES2963784T3 (fr)
FI (2)	FI3405197T3 (fr)
FR (1)	FR24C1053I2 (fr)
HR (1)	HRP20231448T1 (fr)
HU (2)	HUE064192T2 (fr)
IL (4)	IL320757A (fr)
LT (2)	LT3405197T (fr)
MX (2)	MX394358B (fr)
NL (1)	NL301306I2 (fr)
NO (1)	NO2024058I1 (fr)
PL (1)	PL3405197T3 (fr)
PT (1)	PT3405197T (fr)
RS (1)	RS64798B1 (fr)
RU (1)	RU2018130097A (fr)
SG (2)	SG11201805394QA (fr)
SI (1)	SI3405197T1 (fr)
SM (1)	SMT202300415T1 (fr)
TW (2)	TWI783921B (fr)
UA (1)	UA123780C2 (fr)
WO (1)	WO2017125523A1 (fr)
ZA (1)	ZA201804098B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2020275208B2 (en) *	2019-05-15	2025-12-04	Leo Pharma A/S	Formulation of delgocitinib in the form of a cream
WO2022167913A1 (fr) *	2021-02-02	2022-08-11	Pfizer Inc.	Régime posologique pour le traitement de l'eczéma de la main chronique
KR20240027044A (ko) *	2021-07-30	2024-02-29	일라이 릴리 앤드 캄파니	바리시티닙을 사용한 손 습진의 치료
WO2024194105A1 (fr)	2023-03-17	2024-09-26	Leo Pharma A/S	Méthode de traitement de l'eczéma de la main chronique chez des patients ayant un eczéma de main chronique modéré à sévère

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI466885B (zh)	2009-07-31	2015-01-01	Japan Tobacco Inc	含氮螺環化合物及其醫藥用途
US20130302298A1 (en)	2010-11-30	2013-11-14	Bio-K Plus International Inc.	Treatment and prevention of eczema
US20140343034A1 (en) *	2013-04-25	2014-11-20	Japan Tobacco Inc.	Skin barrier function improving agent

2017
- 2017-01-20 CN CN201780006075.2A patent/CN108472297A/zh active Pending
- 2017-01-20 KR KR1020257019206A patent/KR20250088666A/ko active Pending
- 2017-01-20 RU RU2018130097A patent/RU2018130097A/ru unknown
- 2017-01-20 CN CN202311350781.2A patent/CN117159553A/zh active Pending
- 2017-01-20 IL IL320757A patent/IL320757A/en unknown
- 2017-01-20 BR BR112018014769-9A patent/BR112018014769A2/pt not_active Application Discontinuation
- 2017-01-20 WO PCT/EP2017/051133 patent/WO2017125523A1/fr not_active Ceased
- 2017-01-20 CN CN202311350784.6A patent/CN117159554A/zh active Pending
- 2017-01-20 SM SM20230415T patent/SMT202300415T1/it unknown
- 2017-01-20 RS RS20231010A patent/RS64798B1/sr unknown
- 2017-01-20 KR KR1020187024112A patent/KR20180102662A/ko not_active Ceased
- 2017-01-20 US US16/071,209 patent/US20200397787A1/en not_active Abandoned
- 2017-01-20 PL PL17701828.0T patent/PL3405197T3/pl unknown
- 2017-01-20 LT LTEPPCT/EP2017/051133T patent/LT3405197T/lt unknown
- 2017-01-20 DK DK17701828.0T patent/DK3405197T3/da active
- 2017-01-20 SG SG11201805394QA patent/SG11201805394QA/en unknown
- 2017-01-20 TW TW106102111A patent/TWI783921B/zh active
- 2017-01-20 MX MX2018008449A patent/MX394358B/es unknown
- 2017-01-20 FI FIEP17701828.0T patent/FI3405197T3/fi active
- 2017-01-20 ES ES17701828T patent/ES2963784T3/es active Active
- 2017-01-20 CA CA3010547A patent/CA3010547A1/fr active Pending
- 2017-01-20 EP EP23195420.7A patent/EP4257205A3/fr active Pending
- 2017-01-20 HR HRP20231448TT patent/HRP20231448T1/hr unknown
- 2017-01-20 HU HUE17701828A patent/HUE064192T2/hu unknown
- 2017-01-20 IL IL313543A patent/IL313543A/en unknown
- 2017-01-20 JP JP2018538167A patent/JP6929860B2/ja active Active
- 2017-01-20 SI SI201731440T patent/SI3405197T1/sl unknown
- 2017-01-20 PT PT177018280T patent/PT3405197T/pt unknown
- 2017-01-20 IL IL297379A patent/IL297379A/en unknown
- 2017-01-20 TW TW111141449A patent/TWI841027B/zh active
- 2017-01-20 UA UAA201808829A patent/UA123780C2/uk unknown
- 2017-01-20 EP EP17701828.0A patent/EP3405197B1/fr active Active
- 2017-01-20 AU AU2017209932A patent/AU2017209932A1/en not_active Abandoned
- 2017-01-20 SG SG10202006830WA patent/SG10202006830WA/en unknown
2018
- 2018-06-18 IL IL260094A patent/IL260094A/en unknown
- 2018-06-19 ZA ZA2018/04098A patent/ZA201804098B/en unknown
- 2018-07-09 MX MX2022005915A patent/MX2022005915A/es unknown
2022
- 2022-07-08 US US17/811,347 patent/US20230138114A1/en active Pending
- 2022-10-13 AU AU2022252766A patent/AU2022252766B2/en active Active
2023
- 2023-11-10 CY CY20231100643T patent/CY1126388T1/el unknown
2024
- 2024-11-28 AU AU2024266962A patent/AU2024266962A1/en active Pending
- 2024-12-13 NO NO2024058C patent/NO2024058I1/no unknown
- 2024-12-13 NL NL301306C patent/NL301306I2/nl unknown
- 2024-12-15 FR FR24C1053C patent/FR24C1053I2/fr active Active
- 2024-12-17 LT LTPA2024538C patent/LTPA2024538I1/lt unknown
- 2024-12-17 HU HUS2400045C patent/HUS2400045I1/hu unknown
- 2024-12-17 CY CY2024037C patent/CY2024037I1/el unknown
- 2024-12-19 FI FIC20240048C patent/FIC20240048I1/fi unknown

Also Published As

Publication number	Publication date
TWI783921B (zh)	2022-11-21
FR24C1053I1 (fr)	2025-02-21
FI3405197T3 (fi)	2023-11-23
KR20250088666A (ko)	2025-06-17
NL301306I2 (nl)	2024-12-30
BR112018014769A2 (pt)	2018-12-11
JP2019502734A (ja)	2019-01-31
MX2022005915A (es)	2022-06-27
MX394358B (es)	2025-03-24
LT3405197T (lt)	2023-11-27
AU2022252766B2 (en)	2024-08-29
CN108472297A (zh)	2018-08-31
CY2024037I2 (el)	2026-02-25
NO2024058I1 (no)	2024-12-13
RS64798B1 (sr)	2023-11-30
IL297379A (en)	2022-12-01
EP4257205A2 (fr)	2023-10-11
EP3405197B1 (fr)	2023-09-06
RU2018130097A3 (fr)	2020-05-25
IL260094A (en)	2018-07-31
NZ743582A (en)	2024-12-20
FIC20240048I1 (fi)	2024-12-19
TWI841027B (zh)	2024-05-01
UA123780C2 (uk)	2021-06-02
CA3010547A1 (fr)	2017-07-27
EP4257205A3 (fr)	2023-12-20
SI3405197T1 (sl)	2024-03-29
HUS2400045I1 (hu)	2025-01-28
AU2017209932A1 (en)	2018-07-05
LTPA2024538I1 (fr)	2025-01-10
JP6929860B2 (ja)	2021-09-01
CY2024037I1 (el)	2026-02-25
IL313543A (en)	2024-08-01
SG11201805394QA (en)	2018-08-30
CN117159554A (zh)	2023-12-05
US20200397787A1 (en)	2020-12-24
WO2017125523A1 (fr)	2017-07-27
ZA201804098B (en)	2024-10-30
PL3405197T3 (pl)	2024-02-12
KR20180102662A (ko)	2018-09-17
TW201736382A (zh)	2017-10-16
IL320757A (en)	2025-07-01
CY1126388T1 (el)	2026-02-25
HRP20231448T1 (hr)	2024-03-01
AU2022252766A1 (en)	2022-11-03
MX2018008449A (es)	2018-08-09
PT3405197T (pt)	2023-12-06
DK3405197T3 (da)	2023-11-27
ES2963784T3 (es)	2024-04-02
SMT202300415T1 (it)	2024-01-10
EP3405197A1 (fr)	2018-11-28
HUE064192T2 (hu)	2024-02-28
RU2018130097A (ru)	2020-02-21
SG10202006830WA (en)	2020-08-28
TW202332451A (zh)	2023-08-16
CN117159553A (zh)	2023-12-05
US20230138114A1 (en)	2023-05-04
AU2024266962A1 (en)	2024-12-19

Publication	Publication Date	Title
FR25C1001I2 (fr)	2026-01-02	Compositions d'anticorps pour le traitement de tumeurs
FR25C1041I1 (fr)	2025-12-19	Elafibranor pour l'utilisation dans le traitement de la cholangite biliaire primitive
MA45481A (fr)	2018-04-18	Utilisation d'exosomes pour le traitement de maladies
MA49144A (fr)	2020-03-25	Polythérapies pour le traitement du cancer
MA45539A (fr)	2019-05-08	Dihydropyranopyrimidines pour le traitement d'infections virales
EP3504187A4 (fr)	2020-05-06	Utilisation de la pridopidine pour le traitement du déclin fonctionnel
MA47719A (fr)	2020-01-15	Esketamine pour le traitement de la dépression
MA50409A (fr)	2020-08-26	Polythérapies pour le traitement du cancer
MA48637A (fr)	2021-03-17	Polythérapies pour le traitement du cancer
EP3380200A4 (fr)	2019-07-17	Compositions pour le traitement des cheveux
FR24C1053I2 (fr)	2025-12-05	Utilisation du delgocitinib pour le traitement de l'eczéma des mains chronique
EP3503890A4 (fr)	2020-05-06	Utilisation de la pridopidine pour le traitement des dystonies
EP3362065A4 (fr)	2019-06-19	Polythérapie pour le traitement de malignités
EP3541417A4 (fr)	2020-05-27	Immunothérapies d'association pour le traitement du cancer
EP3389645A4 (fr)	2019-12-18	Combinaisons pour le traitement du cancer
EP3380063A4 (fr)	2019-08-07	Compositions pour le traitement des cheveux
EP3359255A4 (fr)	2019-06-12	Polythérapies pour le traitement du cancer
EP3490561A4 (fr)	2020-04-08	Combinaisons pour le traitement du cancer
EP3541379A4 (fr)	2020-05-27	Compositions pour le traitement de l'hypertension
EP3344325A4 (fr)	2019-05-15	Administration locale de médicaments pour le traitement de l'asthme
MA45492A (fr)	2019-05-01	Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
EP3512506A4 (fr)	2020-05-27	Utilisation de la pridopidine pour le traitement du syndrome de rett
EP3334432A4 (fr)	2019-03-13	Cerdulatinib pour le traitement du myélome
EP3630080A4 (fr)	2021-03-10	Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3430400A4 (fr)	2019-10-30	Schémas posologiques pour le traitement d'infections fongiques